News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Jan 25, 2023 Immunic to Participate in Scientific and Investor Conferences in February Nov 17, 2022 Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential Nov 10, 2022 Immunic to Participate in Investor and Scientific Conferences in November and December Nov 3, 2022 Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 27, 2022 Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update Oct 20, 2022 Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate Oct 10, 2022 Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing Oct 4, 2022 Immunic to Participate in Scientific and Industry Conferences in October Sep 20, 2022 Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Sep 1, 2022 Immunic, Inc. to Participate in Investor Conferences in September Aug 16, 2022 Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium Aug 4, 2022 Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Aug 2, 2022 Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference Jul 28, 2022 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update Jul 6, 2022 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén Jun 28, 2022 Immunic to Participate in Industry and Scientific Conferences in July Jun 15, 2022 Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology Jun 8, 2022 Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June Jun 2, 2022 Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update May 10, 2022 Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update May 5, 2022 Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease May 3, 2022 Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update Apr 25, 2022 Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences Mar 16, 2022 Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer Mar 8, 2022 Immunic, Inc. to Participate in Investor and Scientific Conferences in March Show 5102550100 per page«123456»
